Verrica Posts Strong Q3 as YCANTH Momentum Builds and Late-Stage Pipeline Advances
WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) reported third-quarter results that highlight accelerating commercial traction for its lead product, YCANTH®, alongside major regulatory and clinical milestones that broaden …
Verrica Posts Strong Q3 as YCANTH Momentum Builds and Late-Stage Pipeline Advances Read More